2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

Оудард, С.; Angelergues, Antoine; Efstathiou, E.; González, Isabel Chirivella; Gyftaki, R.; Delanoy, Nicolas; Özgüroǧlu, Mustafa; Fléchon, Aude; Guillot, Aline; Moulec, Sylvestre Le; Castellano, Daniel; Esteban, Emilio; Muñarriz, Javier; Balea, Begoña Campos; Ardavanis, Alexandros; Stefanou, Dimitra; Bellmunt, Joaquim

doi:10.1016/s0959-8049(16)31360-0

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent data suggest that regardless of the line of treatment and its sequence, patients who are exposed to as many agents as possible have improvement in OS. (52) Thus, the search and identification of predictive biomarkers of response would be one of the tools to select the best agent and/or the best time to use it. In this scenario, several studies have evaluated the identification of androgen receptor variants (AR-V) as a possible biomarker.…”

Section: Sequencingmentioning

confidence: 99%

Tratamento do câncer avançado de próstata: Onde estamos em 2019?

Monteiro¹,

Soares²,

Oliveira³

et al. 2019

BJOncology

View full text Add to dashboard Cite

In the last decade, important advances have been made in the treatment of metastatic prostate cancer, resulting in a better understanding of the biology underlying the disease, and in the approval of several therapeutic agents such as immunotherapy, new generation antiandrogens, cytotoxic chemotherapies, and radiopharmaceuticals. All these recent advances have been incorporated in clinical guidelines and a critical analysis of the data available should be important to help the decision-making process. In addition, the incorporation of well established therapies in early disease stages have demonstrated a robust overall survival gain for patients with castration-sensitive metastatic prostate cancer. However, no predictive biomarkers of response are available and the selection of the best therapeutic option is still challenging depending on clinical and pathological factors. Many questions related to the optimal sequencing of agents, or comparison of its efficacy remain unanswered.

show abstract

Section: Sequencingmentioning

confidence: 99%

Tratamento do câncer avançado de próstata: Onde estamos em 2019?

Monteiro¹,

Soares²,

Oliveira³

et al. 2019

BJOncology

View full text Add to dashboard Cite

show abstract

“…Další retrospektivní zhodnocení pa cientů s mCRPC ze čtyř evropských zemí prezentoval v roce 2015 Oudard. Prokázal zlepšení OS u pa cientů s trojsekvencí vedle použité dvojsekvence [22]. Problematiku hledání optimální sekvence léčby u pa cientů s mCRPC "komplikuje" i možnost podání ARTA terapie v 1. linii, ještě před aplikací docetaxelu [23,24].…”

Section: Diskuzeunclassified

Docetaxel–Cabazitaxel–Enzalutamide Versus Docetaxel–Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Richter¹,

Dvořák²,

Bartoš³

2017

Klin Onkol

View full text Add to dashboard Cite

No statistically significant differences in OS were found between the sequences docetaxel-cabazitaxel-enzalutamide and docetaxel-enzalutamide.Key words: prostate cancer - metastasis - chemotherapy - targeted hormonal treatment The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 13. 2. 2017Accepted: 20. 3. 2017.

show abstract